Author Archives: admin


Stem Cell Clinic > Articles by: admin

Induced Pluripotent Stem Cells Market Outlook With Key Player, Regions, CAGR of 12.2%, and Specification, Cost Analysis, Price and Gross Margin by…

By Adult Stem Cells

Final Report will add the analysis of the impact of COVID-19 on this industry.

Global Induced Pluripotent Stem Cells Market Research Report 2015-2026 is a historical overview and in-depth study on the current & future market of the Induced Pluripotent Stem Cells industry. The report represents a basic overview of the Induced Pluripotent Stem Cells market share, status, competitor segment with a basic introduction of key vendors, top regions, product types and end industries. This report gives a historical overview of the Induced Pluripotent Stem Cells market trends, growth, revenue, capacity, cost structure, and key drivers analysis.

Request a sample copy of the report https://www.industryresearch.biz/enquiry/request-sample/15898863

The report offers detailed coverage of the Global Induced Pluripotent Stem Cells market which includes industry chain structure, definitions, applications, and classifications. The global Induced Pluripotent Stem Cells market analysis is provided for the international markets including development trends, competitive landscape analysis, investment plan, business strategy, opportunity, and key regions development status. Development policies and plans are discussed as well as manufacturing processes and cost structures are also analyzed. This report also states import/export consumption, supply and demand Figures, cost, industry share, policy, price, revenue and gross margins.

Pluripotent stem cells are embryonic stem cells that have the potential to form all adult cell types and help in repairing of damaged tissues in the human body. An induced pluripotent stem cells, or iPSCs, are taken from any tissue (usually skin or blood) from a child or an adult and is genetically modified to behave like pluripotent stem cells or embryonic stem cells.

iPSCs market is in emerging state mainly due to its ability to make any cell or tissue the body might need to encounter wide range of diseases like diabetes, spinal cord injury, leukaemia or heart disease, these cells can potentially be customized to provide a perfect genetic match for any patient.

Market Analysis and Insights: Global Induced Pluripotent Stem Cells Market

The global Induced Pluripotent Stem Cells market size is projected to reach US$ 92 million by 2026, from US$ 82 million in 2020, at a CAGR of 12.2%% during 2021-2026.

Global Induced Pluripotent Stem Cells Scope and Market Size

Induced Pluripotent Stem Cells market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Induced Pluripotent Stem Cells market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.

Enquire before purchasing this report https://www.industryresearch.biz/enquiry/pre-order-enquiry/15898863

Report Scope And Segmentation Table:

Types:

Hepatocytes, Fibroblasts, Keratinocytes, Amniotic Cells, Others,

Applications:

Academic Research, Drug Development And Discovery, Toxicity Screening, Regenerative Medicine,

Key Players:

Fujifilm Holding Corporation, Astellas Pharma, Fate Therapeutics, Bristol-Myers Squibb Company, ViaCyte, Celgene Corporation, Aastrom Biosciences, Acelity Holdings, StemCells, Japan Tissue Engineering, Organogenesis,

CAGR 2021-2026:

12.2%

Market Size 2020:

USD 82 million

Market Size 2026:

USD 92 million

Historical Years:

2015-2019

Base Year:

2019

With tables and figures helping analyze worldwide Global Induced Pluripotent Stem Cells market growth, this research provides key statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market.

Purchase this report (Price 3900 USD for a single-user license) https://www.industryresearch.biz/purchase/15898863

Induced Pluripotent Stem Cells Market Report Contains Following Points in TOC:

Chapter 1: Induced Pluripotent Stem Cells Market Product Overview, Market Segment, Size, Sales, Growth Rate, Price by Type

Chapter 2: Global Induced Pluripotent Stem Cells Market Competition, Sales, Price, Base Distribution, Sales Area, Product Types, and Trends by Company

Chapter 3: Induced Pluripotent Stem Cells Company Basic Information, Manufacturing Base and Competitors, Product Category, Applications and Specifications, Price and Gross Margin (2015-2026)

Chapter 4: Induced Pluripotent Stem Cells Market Status, Size, CAGR, Revenue, Price, Gross Margin and Outlook by Regions

Chapter 5: Induced Pluripotent Stem Cells Market Sales, and Share Segment by Application/End Users

Chapter 6: Global Induced Pluripotent Stem Cells Market Sales, Revenue, Growth Rate Forecast (2021-2026)

Chapter 7: Induced Pluripotent Stem Cells Upstream Raw Materials, Price, Key Suppliers, Cost Structure, Manufacturing Expenses, Industrial Chain Analysis

Chapter 8: Marketing Strategy Analysis, Distributors

Chapter 9: Research Findings and Conclusion

Detailed TOC of Global Induced Pluripotent Stem Cells Market @ https://www.industryresearch.biz/TOC/15898863

About Us:

Market is changing rapidly with the ongoing expansion of the industry. Advancement in the technology has provided todays businesses with multifaceted advantages resulting in daily economic shifts. Thus, it is very important for a company to comprehend the patterns of the market movements in order to strategize better. An efficient strategy offers the companies with a head start in planning and an edge over the competitors.Industry Research is the credible source for gaining the market reports that will provide you with the lead your business needs.

Contact Info:

Name: Mr. Ajay More

E-mail: [emailprotected]

Organization: Industry Research Biz

Phone: US +1424 253 0807 / UK +44 203 239 8187

Our Other Reports:

Touchless Bathroom Faucets Market 2020 Worldwide Industry Trends, Share, Gross Margin, Size, Future Demand, Analysis by Top Leading Player and Forecast till 2025

Global Consumer Packaged Goods (CPG) Software Market Share, Size 2020 Movements by Latest Trend Analysis, Progression Status, Revenue Expectation to 2025, Research Report by Industry Research Biz

Global E Flute Corrugated Cases/Boxes Market Size 2020 Analysis By Industry Share, End-User Demand, Size Estimation, Growth Factors, Production, Industry Statistics, Overview, and Forecast Report till 2026

Geosynthetics Market 2020 Global Manufacturing Size, Share, Opportunities, Future Trends, Top Key Players, Market Share and Global Analysis by Forecast to 2024

Global Ketone Based Solvents Market Size, Share, 2020 Movements by Development Analysis, Progression Status, Revenue Expectation to 2026, Research Report by Industry Research Biz

Originally posted here:
Induced Pluripotent Stem Cells Market Outlook With Key Player, Regions, CAGR of 12.2%, and Specification, Cost Analysis, Price and Gross Margin by...

Stem Cell Cartilage Regeneration Market 2020 Global Industry Size, Segments, Share and Growth Factor Analysis, Top Key Players Research Report 2026 |…

By Stell Cell Research

Global Stem Cell Cartilage Regeneration Market 2020 Industry Research Report is an inside-out and expert examination on the flow condition of the Global Stem Cell Cartilage Regeneration industry. In addition to that, this latest investigative report sorts the global Stem Cell Cartilage Regeneration market by end client, type, area, and top players/brands. This report further elaborates various factors affecting the market drivers and development. Stem Cell Cartilage Regeneration market also puts forward insights into market size, crucial markers, review, as well as the most recent net edge, income, types, patterns, along with provincial figure and examination.

Get a Sample PDF of report at https://www.researchreportsworld.com/enquiry/request-sample/15528414

The global Stem Cell Cartilage Regeneration market is anticipated to rise at a considerable rate during the forecast period, between 2020 and 2026. In 2020, the market was growing at a steady rate and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.

The Global Stem Cell Cartilage Regeneration market 2020 research provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The Global Stem Cell Cartilage Regeneration Market Share analysis is provided for the international markets including development trends, competitive landscape analysis, and key regions development status. Development policies and plans are discussed as well as manufacturing processes and cost structures are also analyzed.

Final Report will add the analysis of the impact of COVID-19 on this industry.

Under COVID-19 Outbreak, how the Stem Cell Cartilage Regeneration Industry will develop is also analyzed in detail in Chapter 1.7 of the report. In Chapter 2.4, we analyzed industry trends in the context of COVID-19 for Stem Cell Cartilage Regeneration Market. In Chapter 3.5, we analyzed the impact of COVID-19 on the product industry chain based on the upstream and downstream markets for Stem Cell Cartilage Regeneration Market. In Chapters 6 to 10 of the report, we analyze the impact of COVID-19 on various regions and major countries on Stem Cell Cartilage Regeneration Market. In chapter 13.5, the impact of COVID-19 on the future development of the industry is pointed out.

To Understand How COVID-19 Impact is Covered in This Report. Get Sample copy of the report at https://www.researchreportsworld.com/enquiry/request-covid19/15528414

The report can help to understand the market and strategize for business expansion accordingly. In the strategy analysis, it gives insights from marketing channel and market positioning to potential growth strategies, providing in-depth analysis for new entrants or exists competitors in the Stem Cell Cartilage Regeneration industry.This report also states import/export consumption, supply and demand Figures, cost, price, revenue and gross margins. For each manufacturer covered, this report analyzes their Stem Cell Cartilage Regeneration manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.

Global Stem Cell Cartilage Regeneration Market Report 2020 provides exclusive vital statistics, data, information, trends and competitive landscape details in this niche sector.

Enquire before purchasing this report https://www.researchreportsworld.com/enquiry/pre-order-enquiry/15528414

List Of TOP KEY PLAYERS in Stem Cell Cartilage Regeneration Market Report are

Get a Sample Copy of the Stem Cell Cartilage Regeneration Market Report 2020

The report also focuses on global major leading industry players of Global Stem Cell Cartilage Regeneration Market Share providing information such as company profiles, product picture and specification, capacity, production, price, cost, revenue and contact information. Upstream raw materials and equipment and downstream demand analysis is also carried out. With tables and figures helping analyse worldwide Global Stem Cell Cartilage Regeneration Market Forecast this research provides key statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market.

The Global Stem Cell Cartilage Regeneration Market Trends, development and marketing channels are analysed. Finally, the feasibility of new investment projects is assessed and overall research conclusions offered.

Purchase this report (Price 3400 USD for single user license) https://www.researchreportsworld.com/purchase/15528414

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into

On the basis of the end users/applications, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share and growth rate for each application, including

Some of the key questions answered in this report:

Major regions covered in the report:

Major Points from Table of Contents:

1 Report Overview 1.1 Study Scope 1.2 Key Market Segments 1.3 Regulatory Scenario by Region/Country 1.4 Market Investment Scenario Strategic 1.5 Market Analysis by Type 1.5.1 Global Stem Cell Cartilage Regeneration Market Share by Type (2020-2026) 1.5.2 Cell based approaches 1.5.3 Non-cell based approaches 1.6 Market by Application 1.6.1 Global Stem Cell Cartilage Regeneration Market Share by Application (2020-2026) 1.6.2 Hyaline cartilage 1.6.3 Fibrocartilage 1.6.4 Other 1.7 Stem Cell Cartilage Regeneration Industry Development Trends under COVID-19 Outbreak 1.7.1 Global COVID-19 Status Overview 1.7.2 Influence of COVID-19 Outbreak on Stem Cell Cartilage Regeneration Industry Development 2. Global Market Growth Trends 2.1 Industry Trends 2.1.1 SWOT Analysis 2.1.2 Porters Five Forces Analysis 2.2 Potential Market and Growth Potential Analysis 2.3 Industry News and Policies by Regions 2.3.1 Industry News 2.3.2 Industry Policies 2.4 Industry Trends Under COVID-19 3 Value Chain of Stem Cell Cartilage Regeneration Market 3.1 Value Chain Status 3.2 Stem Cell Cartilage Regeneration Manufacturing Cost Structure Analysis 3.2.1 Production Process Analysis 3.2.2 Manufacturing Cost Structure of Stem Cell Cartilage Regeneration 3.2.3 Labor Cost of Stem Cell Cartilage Regeneration 3.2.3.1 Labor Cost of Stem Cell Cartilage Regeneration Under COVID-19 3.3 Sales and Marketing Model Analysis 3.4 Downstream Major Customer Analysis (by Region) 3.5 Value Chain Status Under COVID-19 4 Players Profiles 4.1 BioTissue Technologies 4.1.1 BioTissue Technologies Basic Information 4.1.2 Stem Cell Cartilage Regeneration Product Profiles, Application and Specification 4.1.3 BioTissue Technologies Stem Cell Cartilage Regeneration Market Performance (2015-2020) 4.1.4 BioTissue Technologies Business Overview 4.2 Anika Therapeutics 4.2.1 Anika Therapeutics Basic Information 4.2.2 Stem Cell Cartilage Regeneration Product Profiles, Application and Specification 4.2.3 Anika Therapeutics Stem Cell Cartilage Regeneration Market Performance (2015-2020) 4.2.4 Anika Therapeutics Business Overview 4.3 Biomet 4.3.1 Biomet Basic Information 4.3.2 Stem Cell Cartilage Regeneration Product Profiles, Application and Specification 4.3.3 Biomet Stem Cell Cartilage Regeneration Market Performance (2015-2020) 4.3.4 Biomet Business Overview 4.4 Smith & Nephew 4.4.1 Smith & Nephew Basic Information 4.4.2 Stem Cell Cartilage Regeneration Product Profiles, Application and Specification 4.4.3 Smith & Nephew Stem Cell Cartilage Regeneration Market Performance (2015-2020) 4.4.4 Smith & Nephew Business Overview 4.5 EMD Serono 4.5.1 EMD Serono Basic Information 4.5.2 Stem Cell Cartilage Regeneration Product Profiles, Application and Specification 4.5.3 EMD Serono Stem Cell Cartilage Regeneration Market Performance (2015-2020) 4.5.4 EMD Serono Business Overview 4.6 Zimmer 4.6.1 Zimmer Basic Information 4.6.2 Stem Cell Cartilage Regeneration Product Profiles, Application and Specification 4.6.3 Zimmer Stem Cell Cartilage Regeneration Market Performance (2015-2020) 4.6.4 Zimmer Business Overview 4.7 CellGenix 4.7.1 CellGenix Basic Information 4.7.2 Stem Cell Cartilage Regeneration Product Profiles, Application and Specification 4.7.3 CellGenix Stem Cell Cartilage Regeneration Market Performance (2015-2020) 4.7.4 CellGenix Business Overview 4.8 Sanofi Aventis 4.8.1 Sanofi Aventis Basic Information 4.8.2 Stem Cell Cartilage Regeneration Product Profiles, Application and Specification 4.8.3 Sanofi Aventis Stem Cell Cartilage Regeneration Market Performance (2015-2020) 4.8.4 Sanofi Aventis Business Overview 4.9 DePuy (Johnson & Johnson) 4.9.1 DePuy (Johnson & Johnson) Basic Information 4.9.2 Stem Cell Cartilage Regeneration Product Profiles, Application and Specification 4.9.3 DePuy (Johnson & Johnson) Stem Cell Cartilage Regeneration Market Performance (2015-2020) 4.9.4 DePuy (Johnson & Johnson) Business Overview 4.10 Genzyme 4.10.1 Genzyme Basic Information 4.10.2 Stem Cell Cartilage Regeneration Product Profiles, Application and Specification 4.10.3 Genzyme Stem Cell Cartilage Regeneration Market Performance (2015-2020) 4.10.4 Genzyme Business Overview 5 Global Stem Cell Cartilage Regeneration Market Analysis by Regions 5.1 Global Stem Cell Cartilage Regeneration Sales, Revenue and Market Share by Regions 5.1.1 Global Stem Cell Cartilage Regeneration Sales by Regions (2015-2020) 5.1.2 Global Stem Cell Cartilage Regeneration Revenue by Regions (2015-2020) 5.2 North America Stem Cell Cartilage Regeneration Sales and Growth Rate (2015-2020) 5.3 Europe Stem Cell Cartilage Regeneration Sales and Growth Rate (2015-2020) 5.4 Asia-Pacific Stem Cell Cartilage Regeneration Sales and Growth Rate (2015-2020) 5.5 Middle East and Africa Stem Cell Cartilage Regeneration Sales and Growth Rate (2015-2020) 5.6 South America Stem Cell Cartilage Regeneration Sales and Growth Rate (2015-2020)

Continued

Browse complete table of contents at https://www.researchreportsworld.com/TOC/15528414

About Us:

Research Reports World is the credible source for gaining the market reports that will provide you with the lead your business needs. At Research Reports World, our objective is providing a platform for many top-notch market research firms worldwide to publish their research reports, as well as helping the decision makers in finding most suitable market research solutions under one roof. Our aim is to provide the best solution that matches the exact customer requirements. This drives us to provide you with custom or syndicated research reports.

Contact Us:

Name: Ajay More

Email: [emailprotected]

Phone: US+1424 253 0807/UK+44 203 239 8187

Other Reports Here:

Chlorinated Paraffins Market Size Research, Business Opportunities, Top Manufacture, Industry Growth, Industry Share Report, Regional Analysis and Global Forecast to 2025 Research Reports World

Citrus Fiber Market Size, Global Industry Share, Trends, Sales Revenue, Industry Growth, Development Status, Top Leaders, Future Plans and Opportunity Assessment 2025

Wardrobe Boxes Market Size, Share, Industry Overview, Key Players Analysis, Emerging Opportunities, Comprehensive Research Study, Competitive Landscape and Potential of Industry from 2020-2026

Mycoplasma Testing Market Size, Share, Revenue, Latest Trends, Business Boosting Strategies, CAGR Status, Growth Opportunities and Forecast 2026 Research Reports World

Vehicles Armor Market Size, Share, Global Industry Growth, Development, Revenue, Future Analysis, Business Prospects and Forecast to 2026 Research Reports World

Power Sensors Market Size, share Global Industry Trends, Growth Drivers, Demands, Business Opportunities and Demand Forecast to 2026

Boardroom Table Market Size, Share Industry Analysis By Future Demand, Top Players, Opportunities, Revenue and Growth Rate Through 2026 Research Reports World

Cleansing Cotton Market Size, Research Report to 2026 Industry, Growth Share, Future Trends, Price, Top Key Players Review, Business Opportunities, Demand and Global Analysis by Forecast

Exhaust Silencer Market Size, Research Reports Global Industry, Share, In-Depth Qualitative Insights, Explosive Growth Opportunity, Regional Analysis by Research Reports World

Automatic Terminal Market Size, Share, Revenue, Latest Trends, Business Boosting Strategies, CAGR Status, Growth Opportunities and Forecast 2026 Research Reports World

View post:
Stem Cell Cartilage Regeneration Market 2020 Global Industry Size, Segments, Share and Growth Factor Analysis, Top Key Players Research Report 2026 |...

Global Stem Cell Assay Market 2020: Business Opportunities, Industry Size & Share, Key Applications, Demands, Growth, Trends Analysis and Forecast…

By Stell Cell Research

Final Report will add the analysis of the impact of COVID-19 on this industry.

Global Stem Cell Assay Market Research Report 2015-2026 is a historical overview and in-depth study on the current & future market of the Stem Cell Assay industry. The report represents a basic overview of the Stem Cell Assay market share, status, competitor segment with a basic introduction of key vendors, top regions, product types and end industries. This report gives a historical overview of the Stem Cell Assay market trends, growth, revenue, capacity, cost structure, and key drivers analysis.

Request a sample copy of the report https://www.industryresearch.biz/enquiry/request-sample/15874875

The report offers detailed coverage of the Global Stem Cell Assay market which includes industry chain structure, definitions, applications, and classifications. The global Stem Cell Assay market analysis is provided for the international markets including development trends, competitive landscape analysis, investment plan, business strategy, opportunity, and key regions development status. Development policies and plans are discussed as well as manufacturing processes and cost structures are also analyzed. This report also states import/export consumption, supply and demand Figures, cost, industry share, policy, price, revenue and gross margins.

The demand of global stem cell assay is increasing.

Market Analysis and Insights: Global Stem Cell Assay Market

The global Stem Cell Assay market size is projected to reach US$ 843 million by 2026, from US$ 750.5 million in 2020, at a CAGR of 11.4%% during 2021-2026.

Global Stem Cell Assay Scope and Market Size

Stem Cell Assay market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Stem Cell Assay market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.

Enquire before purchasing this report https://www.industryresearch.biz/enquiry/pre-order-enquiry/15874875

Report Scope And Segmentation Table:

Types:

Viability, Purification, Identification,

Applications:

Regenerative Medicine, Clinical Research,

Key Players:

Merck, Thermo Fisher Scientific, GE Healthcare, Agilent Technologies, Bio-Rad Laboratories, Promega, Cell Biolabs, PerkinElmer, Miltenyi Biotec, HemoGenix, Bio-Techne, STEMCELL,

CAGR 2021-2026:

11.4%

Market Size 2020:

USD 750.5 million

Market Size 2026:

USD 843 million

Historical Years:

2015-2019

Base Year:

2019

With tables and figures helping analyze worldwide Global Stem Cell Assay market growth, this research provides key statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market.

Purchase this report (Price 3900 USD for a single-user license) https://www.industryresearch.biz/purchase/15874875

Stem Cell Assay Market Report Contains Following Points in TOC:

Chapter 1: Stem Cell Assay Market Product Overview, Market Segment, Size, Sales, Growth Rate, Price by Type

Chapter 2: Global Stem Cell Assay Market Competition, Sales, Price, Base Distribution, Sales Area, Product Types, and Trends by Company

Chapter 3: Stem Cell Assay Company Basic Information, Manufacturing Base and Competitors, Product Category, Applications and Specifications, Price and Gross Margin (2015-2026)

Chapter 4: Stem Cell Assay Market Status, Size, CAGR, Revenue, Price, Gross Margin and Outlook by Regions

Chapter 5: Stem Cell Assay Market Sales, and Share Segment by Application/End Users

Chapter 6: Global Stem Cell Assay Market Sales, Revenue, Growth Rate Forecast (2021-2026)

Chapter 7: Stem Cell Assay Upstream Raw Materials, Price, Key Suppliers, Cost Structure, Manufacturing Expenses, Industrial Chain Analysis

Chapter 8: Marketing Strategy Analysis, Distributors

Chapter 9: Research Findings and Conclusion

Detailed TOC of Global Stem Cell Assay Market @ https://www.industryresearch.biz/TOC/15874875

About Us:

Market is changing rapidly with the ongoing expansion of the industry. Advancement in the technology has provided todays businesses with multifaceted advantages resulting in daily economic shifts. Thus, it is very important for a company to comprehend the patterns of the market movements in order to strategize better. An efficient strategy offers the companies with a head start in planning and an edge over the competitors.Industry Research is the credible source for gaining the market reports that will provide you with the lead your business needs.

Contact Info:

Name: Mr. Ajay More

E-mail: [emailprotected]

Organization: Industry Research Biz

Phone: US +1424 253 0807 / UK +44 203 239 8187

Our Other Reports:

Global Folding Knives Market Size 2020 Growing Rapidly with Recent Developments, Industry Share, Trends, Demand, Revenue, Key Findings and Latest Technology, Forecast Research Report 2026

Domestic Sewing Machine Market Size 2020 Global Industry Trends, Future Growth, Regional Overview, Market Share, Revenue, and Forecast Outlook till 2026, Says Industry Research Biz

Soundproof Glass Market Size 2020 By Industry Share, Key Findings, Company Profiles, Growth Strategy, Developing Technologies, Demand, Investment Opportunities and Forecast by Regions till 2026

Oleo Chemicals Market Size and Share 2020 by Industry Impact, Sales Revenue, Future Demands, Growth Factors and Drivers, Emerging Trends, Competitive Landscape and Forecast to 2026

Global Oil Skimmer Market Size 2020 Industry Overview, Shares, Growing Demand, Growth, Production, Types, Applications and 2026 Forecast Report by Industry Research Biz

Global Mints Market Size 2020 Industry Overview, Shares, Growing Demand, Growth, Production, Types, Applications and 2026 Forecast Report by Industry Research Biz

Perfume Packaging Market Size 2020 Key Manufacturers, Industry Share, Investment Opportunities, Future Trends, Market Impact, Revenue, Demand and Analysis by Forecast 2026

Follow this link:
Global Stem Cell Assay Market 2020: Business Opportunities, Industry Size & Share, Key Applications, Demands, Growth, Trends Analysis and Forecast...

New Study Finds Novel Hyperbaric Oxygen Therapy Protocol Can Improve Cognitive Function of Healthy Older Adults – Yahoo Finance

By Stell Cell Research

Research from the Sagol Center for Hyperbaric Medicine and Research Published in Peer Reviewed Journal Aging first to Show Enhanced Brain Function and Improved Cognitive Capabilities Resulting from Novel Hyperbaric Oxygen Therapy Treatment

TEL AVIV, Israel, July 15, 2020 /PRNewswire/ -- The Sagol Center for Hyperbaric Medicine and Researchat Shamir Medical Center, and Tel Aviv University today announced that, for the first time in humans, a peer-reviewed study has demonstrated that hyperbaric oxygen therapy (HBOT) can significantly enhance the cognitive performance of healthy older adults.

The main areas of improvement were attention, information processing speed and executive function, in addition to global cognitive function, all of which typically decline with age. Moreover, there was a significant correlation between the cognitive changes and improved cerebral blood flow in specific brain locations.

The study was published on July 15, 2020 in the peer reviewed journal Aging, entitled: Cognitive enhancement of healthy older adults using hyperbaric oxygen: a randomized controlled trial.

Professor Shai Efrati and Dr. Amir Hadanny designed the study based on a unique HBOT protocol developed at the Sagol Center over the past 10 years. The randomized controlled clinical trial included 63 healthy adults (>64) who underwent either HBOT(n=33) or a control period (n=30) for three months. The study's primary endpoint included a change in general cognitive function measured by a standardized comprehensive battery of computerized cognitive assessments before and after the intervention or control. Cerebral blood flow (CBF) was evaluated by a novel magnetic resonance imaging technique for brain perfusion.

"Age-related cognitive and functional decline has become a significant concern in the Western world. Major research efforts around the world are focused on improving cognitive performance of the so-called 'normal' aging population," said Prof. Efrati, Director of the Sagol Center for Hyperbaric Medicine and Research. "In our study, for the first time in humans, we have found an effective and safe medical intervention that can address this unwanted consequence of our age-related deterioration."

"Over years of research, we have developed an advanced understanding of HBOT's ability to restore brain function. In the past, we demonstrated HBOT's potential to improve/treat brain injuries such as stroke, traumatic brain injury and anoxic brain injury (due to sustained lack of oxygen supply) by increasing brain blood flow and metabolism," explained Amir Hadanny, MDS, Chief Medical Research Officer of TheSagol Center for Hyperbaric Medicine and Research and author of the aging study. "This landmark research could have a far-reaching impact on the way we view the aging process and the ability to treat its symptoms."

During HBOT, the patient breaths in pure oxygen in a pressurized chamber where the air pressure is increased to twice that of normal air. This process increases oxygen solubility in the blood that travels throughout the body. The added oxygen stimulates the release of growth factors and stem cells, which promote healing. HBOT has been applied worldwide mostly to treat chronic non-healing wounds.

There is a growing body of evidence on the regenerative effects of HBOT. Sagol Center researchers have demonstrated that the combined action of delivering high levels of oxygen (hyperoxia) and pressure (hyperbaric environment), leads to significant improvement in tissue oxygenation while targeting both oxygen and pressure sensitive genes, resulting in restored and enhanced tissue metabolism. Moreover, these targeted genes induce stem cell proliferation, reduce inflammation and induce generation of new blood vessels and tissue repair mechanisms.

"The occlusion of small blood vessels, similar to the occlusions which may develop in the pipes of an 'aging' home, is a dominant element in the human aging process. This led us to speculate that HBOT may affect brain performance of the aging population," Prof. Efrati explained. "We found that HBOT induced a significant increase in brain blood flow, which correlated with cognitive improvement, confirming our theory. One can conjecture that similar beneficial effects of HBOT can be induced in other organs of the aging body. These will be investigated in our upcoming research."

Story continues

The research group leader, Professor Shai Efrati, who serves as Director of The Sagol Center for Hyperbaric Medicine and Research, also disclosed his role with Aviv Scientific LTD, which has developed a comprehensive program that includes HBOT treatment, cognitive and physical training and nutritional coaching, to enhance brain and body performance of aging adults based on the Sagol HBOT protocol at Aviv Clinics. Prof. Efrati serves as Chair of Aviv Scientific's Medical Advisory Board.

About the Sagol Center for Hyperbaric Medicine and Research

The Sagol Center for Hyperbaric Medicine and Research at Shamir Medical Center (formerly Assaf Harofeh Medical Center), is a global leader in advancing the understanding of the impact of hyperbaric medicine on cognitive and physical function. Serving as one of the largest Hyperbaric centers worldwide, the Sagol Center offers highly advanced large multiplace chambers, treating more than 200 patients daily. Research conducted at the Center has proven that brain rejuvenation is possible across a wide range of neurological pathologies and illnesses.

Media Contact:

Nicole Grubner Finn Partners for The Sagol Center for Hyperbaric Medicine and Research +1-929-222-8011 nicole.grubner@finnpartners.com

View original content:http://www.prnewswire.com/news-releases/new-study-finds-novel-hyperbaric-oxygen-therapy-protocol-can-improve-cognitive-function-of-healthy-older-adults-301093757.html

SOURCE The Sagol Center for Hyperbaric Medicine and Research

More here:
New Study Finds Novel Hyperbaric Oxygen Therapy Protocol Can Improve Cognitive Function of Healthy Older Adults - Yahoo Finance

Animal Stem Cell Therapy Market Forecast by 2026: Expected to reach USD 291.6 million, at a CAGR of 37.3% during 2021-2026 – Cole of Duty

By Stem Cell Treatment

Final Report will add the analysis of the impact of COVID-19 on this industry.

Global Animal Stem Cell Therapy Market Research Report 2015-2026 is a historical overview and in-depth study on the current & future market of the Animal Stem Cell Therapy industry. The report represents a basic overview of the Animal Stem Cell Therapy market share, status, competitor segment with a basic introduction of key vendors, top regions, product types and end industries. This report gives a historical overview of the Animal Stem Cell Therapy market trends, growth, revenue, capacity, cost structure, and key drivers analysis.

Request a sample copy of the report https://www.industryresearch.biz/enquiry/request-sample/15904448

The report offers detailed coverage of the Global Animal Stem Cell Therapy market which includes industry chain structure, definitions, applications, and classifications. The global Animal Stem Cell Therapy market analysis is provided for the international markets including development trends, competitive landscape analysis, investment plan, business strategy, opportunity, and key regions development status. Development policies and plans are discussed as well as manufacturing processes and cost structures are also analyzed. This report also states import/export consumption, supply and demand Figures, cost, industry share, policy, price, revenue and gross margins.

Animal stem cell therapy is a usage of animals stem cell to treat a disease or disorder. The ability of stem cell is to divide and differentiate into a cell with specialized function useful for repairing body tissues damaged by injury or disease. The animal stem cell therapy process involves three steps which include collection of stem cell sample from animals and preparing the sample to concentrate the stem cells. Finally, the therapy includes transferring the stem cells into the injured site for treatment. Animal stem cell therapy increases the expectancy of life in animals with no side effects. It is available for the treatment of arthritis, degenerative joint disorders, tendon, and ligaments injuries in animals. Stem cell therapy is most often used to treat dogs, cats, and horses. But recent developments made it possible to use animal stem cell therapy in tiger, pig, etc. Present animal stem cell therapy is studied in treatments of the inflammatory bowel, kidney, liver, heart and immune-mediated diseases respectively.

The classification of animal stem cell therapy includes dogs, horses and others. And the proportion of dogs in 2017 is about 50.42%, and the proportion is in increasing trend from 2013 to 2017.

Market Analysis and Insights: Global Animal Stem Cell Therapy Market

In 2019, the global Animal Stem Cell Therapy market size was US$ 31 million and it is expected to reach US$ 291.6 million by the end of 2026, with a CAGR of 37.3% during 2021-2026.

Global Animal Stem Cell Therapy Scope and Market Size

Animal Stem Cell Therapy market is segmented by region, by country, company, type, application and by sales channels. Players, stakeholders, and other participants in the global Animal Stem Cell Therapy market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region, by country, company, type, application and by sales channels for the period 2015-2026.

Enquire before purchasing this report https://www.industryresearch.biz/enquiry/pre-order-enquiry/15904448

Report Scope And Segmentation Table:

Types:

Dogs, Horses, Others,

Applications:

Veterinary Hospitals, Research Organizations,

Key Players:

Medivet Biologics LLC, VETSTEM BIOPHARMA, J-ARM, U.S. Stem Cell, Inc, VetCell Therapeutics, Celavet Inc., Magellan Stem Cells, Kintaro Cells Power, Animal Stem Care, Animal Cell Therapies, Cell Therapy Sciences, Animacel,

CAGR 2021-2026:

37.3%

Market Size 2020:

USD 31 million

Market Size 2026:

USD 291.6 million

Historical Years:

2015-2019

Base Year:

2019

With tables and figures helping analyze worldwide Global Animal Stem Cell Therapy market growth, this research provides key statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market.

Purchase this report (Price 5900 USD for a single-user license) https://www.industryresearch.biz/purchase/15904448

Animal Stem Cell Therapy Market Report Contains Following Points in TOC:

Chapter 1: Animal Stem Cell Therapy Market Product Overview, Market Segment, Size, Sales, Growth Rate, Price by Type

Chapter 2: Global Animal Stem Cell Therapy Market Competition, Sales, Price, Base Distribution, Sales Area, Product Types, and Trends by Company

Chapter 3: Animal Stem Cell Therapy Company Basic Information, Manufacturing Base and Competitors, Product Category, Applications and Specifications, Price and Gross Margin (2015-2026)

Chapter 4: Animal Stem Cell Therapy Market Status, Size, CAGR, Revenue, Price, Gross Margin and Outlook by Regions

Chapter 5: Animal Stem Cell Therapy Market Sales, and Share Segment by Application/End Users

Chapter 6: Global Animal Stem Cell Therapy Market Sales, Revenue, Growth Rate Forecast (2021-2026)

Chapter 7: Animal Stem Cell Therapy Upstream Raw Materials, Price, Key Suppliers, Cost Structure, Manufacturing Expenses, Industrial Chain Analysis

Chapter 8: Marketing Strategy Analysis, Distributors

Chapter 9: Research Findings and Conclusion

Detailed TOC of Global Animal Stem Cell Therapy Market @ https://www.industryresearch.biz/TOC/15904448

About Us:

Market is changing rapidly with the ongoing expansion of the industry. Advancement in the technology has provided todays businesses with multifaceted advantages resulting in daily economic shifts. Thus, it is very important for a company to comprehend the patterns of the market movements in order to strategize better. An efficient strategy offers the companies with a head start in planning and an edge over the competitors.Industry Research is the credible source for gaining the market reports that will provide you with the lead your business needs.

Contact Info:

Name: Mr. Ajay More

E-mail: [emailprotected]

Organization: Industry Research Biz

Phone: US +1424 253 0807 / UK +44 203 239 8187

Our Other Reports:

Global Telecom System Integration Market Size 2020 Industry Recent Developments, Emerging Trends, Growth, CAGR of 6.1%, Progression Status, Latest Technology, and Forecast Research Report 2026

Fiber Optic Coatings Market Size 2020 Analysis By Business Share, Strategies, Investment Opportunities, Revenue Expectation, Future Trends, Prominent Players, Covid-19 Impact Analysis and Forecast till 2026

Contact Lens Solution Market Size 2020 By Trends Evaluation, Leading Players Updates, Consumer-Demand, Consumption, Recent Developments, Strategies, Market Impact and Forecast till 2026, with CAGR of 3.8%, Says Industry Research Biz

Global Surge Protection Devices (SPDs) Market Size & Share, 2020 Movements by Latest Trend Analysis, Progression Status, Revenue Expectation to 2026, Research Report by Industry Research Biz

Nail Polish Market Size 2020 By Global Business Trends, Share, Future Demand, Progress Insight, Statistics, Key Regions, Leading Players Updates and Forecast to 2025 by Industry Research Biz

Continued here:
Animal Stem Cell Therapy Market Forecast by 2026: Expected to reach USD 291.6 million, at a CAGR of 37.3% during 2021-2026 - Cole of Duty

New Study Finds Novel Hyperbaric Oxygen Therapy Protocol Can Improve Cognitive Function of Healthy Older Adults – PRNewswire

By Stem Cell Medicine

TEL AVIV, Israel, July 15, 2020 /PRNewswire/ -- The Sagol Center for Hyperbaric Medicine and Researchat Shamir Medical Center, and Tel Aviv University today announced that, for the first time in humans, a peer-reviewed study has demonstrated that hyperbaric oxygen therapy (HBOT) can significantly enhance the cognitive performance of healthy older adults.

The main areas of improvement were attention, information processing speed and executive function, in addition to global cognitive function, all of which typically decline with age. Moreover, there was a significant correlation between the cognitive changes and improved cerebral blood flow in specific brain locations.

The study was published on July 15, 2020 in the peer reviewed journal Aging, entitled: Cognitive enhancement of healthy older adults using hyperbaric oxygen: a randomized controlled trial.

Professor Shai Efrati and Dr. Amir Hadanny designed the study based on a unique HBOT protocol developed at the Sagol Center over the past 10 years. The randomized controlled clinical trial included 63 healthy adults (>64) who underwent either HBOT(n=33) or a control period (n=30) for three months. The study's primary endpoint included a change in general cognitive function measured by a standardized comprehensive battery of computerized cognitive assessments before and after the intervention or control. Cerebral blood flow (CBF) was evaluated by a novel magnetic resonance imaging technique for brain perfusion.

"Age-related cognitive and functional decline has become a significant concern in the Western world. Major research efforts around the world are focused on improving cognitive performance of the so-called 'normal' aging population," said Prof. Efrati, Director of the Sagol Center for Hyperbaric Medicine and Research. "In our study, for the first time in humans, we have found an effective and safe medical intervention that can address this unwanted consequence of our age-related deterioration."

"Over years of research, we have developed an advanced understanding of HBOT's ability to restore brain function. In the past, we demonstrated HBOT's potential to improve/treat brain injuries such as stroke, traumatic brain injury and anoxic brain injury (due to sustained lack of oxygen supply) by increasing brain blood flow and metabolism," explained Amir Hadanny, MDS, Chief Medical Research Officer of TheSagol Center for Hyperbaric Medicine and Research and author of the aging study. "This landmark research could have a far-reaching impact on the way we view the aging process and the ability to treat its symptoms."

During HBOT, the patient breaths in pure oxygen in a pressurized chamber where the air pressure is increased to twice that of normal air. This process increases oxygen solubility in the blood that travels throughout the body. The added oxygen stimulates the release of growth factors and stem cells, which promote healing. HBOT has been applied worldwide mostly to treat chronic non-healing wounds.

There is a growing body of evidence on the regenerative effects of HBOT. Sagol Center researchers have demonstrated that the combined action of delivering high levels of oxygen (hyperoxia) and pressure (hyperbaric environment), leads to significant improvement in tissue oxygenation while targeting both oxygen and pressure sensitive genes, resulting in restored and enhanced tissue metabolism. Moreover, these targeted genes induce stem cell proliferation, reduce inflammation and induce generation of new blood vessels and tissue repair mechanisms.

"The occlusion of small blood vessels, similar to the occlusions which may develop in the pipes of an 'aging' home, is a dominant element in the human aging process. This led us to speculate that HBOT may affect brain performance of the aging population," Prof. Efrati explained. "We found that HBOT induced a significant increase in brain blood flow, which correlated with cognitive improvement, confirming our theory. One can conjecture that similar beneficial effects of HBOT can be induced in other organs of the aging body. These will be investigated in our upcoming research."

The research group leader, Professor Shai Efrati, who serves as Director of The Sagol Center for Hyperbaric Medicine and Research, also disclosed his role with Aviv Scientific LTD, which has developed a comprehensive program that includes HBOT treatment, cognitive and physical training and nutritional coaching, to enhance brain and body performance of aging adults based on the Sagol HBOT protocol at Aviv Clinics. Prof. Efrati serves as Chair of Aviv Scientific's Medical Advisory Board.

About the Sagol Center for Hyperbaric Medicine and Research

The Sagol Center for Hyperbaric Medicine and Research at Shamir Medical Center (formerly Assaf Harofeh Medical Center), is a global leader in advancing the understanding of the impact of hyperbaric medicine on cognitive and physical function. Serving as one of the largest Hyperbaric centers worldwide, the Sagol Center offers highly advanced large multiplace chambers, treating more than 200 patients daily. Research conducted at the Center has proven that brain rejuvenation is possible across a wide range of neurological pathologies and illnesses.

Media Contact:

Nicole Grubner Finn Partners for The Sagol Center for Hyperbaric Medicine and Research +1-929-222-8011 [emailprotected]

SOURCE The Sagol Center for Hyperbaric Medicine and Research

https://www.shamir.org/en/unique-pages-default-aspx/the-sagol-center-for-hyperbaric-medicine-and-research/

Originally posted here:
New Study Finds Novel Hyperbaric Oxygen Therapy Protocol Can Improve Cognitive Function of Healthy Older Adults - PRNewswire

Orchard Therapeutics Announces Global License Agreements for Stable Cell Line Technology from GSK – BioSpace

By Stem Cell Treatment

BOSTON and LONDON, July 15, 2020 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the company has entered into two worldwide royalty-bearing license agreements with GlaxoSmithKline plc (GSK) (LSE/NYSE: GSK) for use of their proprietary lentiviral stable cell line technology (LV-SCLT) for Orchards investigational hematopoietic stem cell gene therapies for Wiskott Aldrich syndrome (OTL-103 for WAS) and transfusion-dependent beta thalassemia (OTL-300 for TDT).

Utilization of a stable cell line provides an opportunity to generate lentiviral vector of consistently high titer and eliminates the need to purchase plasmids prior to the production of each viral vector batch, providing more efficient production processes and shorter lead times, said Bobby Gaspar, M.D., Ph.D., chief executive officer of Orchard. By increasing the efficiency of the vector manufacturing process, this technology can provide a key competitive advantage and supports our focus on manufacturing innovations that enable commercial scalability.

The LV-SCLT permanently and stably enables all the lentiviral vector components to be introduced into a cell line in one step. Selection and expansion of a resulting clonal producer line in either suspension or adherent culture can deliver consistent levels of high titer lentiviral production comparable to those seen using conventional methods. An overview of this technology, co-authored by Orchard and GSK scientists, was presented at the European Society of Gene & Cell Therapy (ESGCT) Annual Congress in October 2019 using work done in the OTL-300 program for TDT*. Under the licenses, GSK has granted patents and pending patent applications related to its LV-SCLT**.

Gaspar continued, We believe the work completed with OTL-300 utilizing a stable cell line can be leveraged and applied to future development plans in OTL-103 for WAS, which will be especially useful in a commercial setting given the large number of patients diagnosed and living with the disease.

Orchard plans to submit a biologics license application (BLA) and marketing authorization application (MAA) for OTL-103 for the treatment of WAS in the U.S. and EU, respectively, in 2021.

The terms of the license are not expected to have a material impact on Orchards financial position or near-term cash needs.

About OTL-103 and WAS OTL-103 is an ex vivo autologous hematopoietic stem cell gene therapy in development for the treatment of Wiskott Aldrich syndrome (WAS). WAS is a life-threatening inherited immune disorder that primarily affects males and is characterized by recurrent and severe infections, autoimmunity, eczema and severe bleeding episodes. It is caused by a mutation in the gene that produces the WAS protein, which results in abnormal function of white blood cells and low platelets. Without treatment, the median survival for children born with WAS is 14 years of age. The global incidence of WAS is estimated to be about one in every 100,000 male births per year***.

About Orchard Orchard Therapeutics is a global gene therapy leader dedicated to transforming the lives of people affected by rare diseases through the development of innovative, potentially curative gene therapies. Our ex vivo autologous gene therapy approach harnesses the power of genetically modified blood stem cells and seeks to correct the underlying cause of disease in a single administration. In 2018, Orchard acquired GSKs rare disease gene therapy portfolio, which originated from a pioneering collaboration between GSK and the San Raffaele Telethon Institute for Gene Therapy in Milan, Italy. Orchard now has one of the deepest and most advanced gene therapy product candidate pipelines in the industry spanning multiple therapeutic areas where the disease burden on children, families and caregivers is immense and current treatment options are limited or do not exist.

Orchard has its global headquarters in London and U.S. headquarters in Boston. For more information, please visit http://www.orchard-tx.com, and follow us on Twitter and LinkedIn.

Availability of Other Information About Orchard Investors and others should note that Orchard communicates with its investors and the public using the company website (www.orchard-tx.com), the investor relations website (ir.orchard-tx.com), and on social media (Twitter and LinkedIn), including but not limited to investor presentations and investor fact sheets, U.S. Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that Orchard posts on these channels and websites could be deemed to be material information. As a result, Orchard encourages investors, the media, and others interested in Orchard to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from time to time on Orchards investor relations website and may include additional social media channels. The contents of Orchards website or these channels, or any other website that may be accessed from its website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933.

Forward-Looking Statements This press release contains certain forward-looking statements about Orchards strategy, future plans and prospects, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include express or implied statements relating to, among other things, Orchards business strategy and goals, the therapeutic potential of Orchards product candidates, including the product candidate or candidates referred to in this release, Orchards expectations regarding the timing of regulatory submissions for its product candidates, the size of the potential markets for Orchards product candidates, and the effectiveness, efficiencies expected from and expected use of stable cell line technology. These statements are neither promises nor guarantees and are subject to a variety of risks and uncertainties, many of which are beyond Orchards control, which could cause actual results to differ materially from those contemplated in these forward-looking statements. In particular, these risks and uncertainties include, without limitation: the severity of the impact of the COVID-19 pandemic on Orchards business, including on clinical development and commercial programs; the risk that any one or more of Orchards product candidates, including the product candidate or candidates referred to in this release, will not be approved, successfully developed or commercialized; the risk of cessation or delay of any of Orchards ongoing or planned clinical trials; the risk that Orchard may not successfully recruit or enroll a sufficient number of patients for its clinical trials; the risk that prior results, such as signals of safety, activity or durability of effect, observed from preclinical studies or clinical trials will not be replicated or will not continue in ongoing or future studies or trials involving Orchards product candidates; the delay of any of Orchards regulatory submissions; the failure to obtain marketing approval from the applicable regulatory authorities for any of Orchards product candidates or the receipt of restricted marketing approvals; the risk of delays in Orchards ability to commercialize its product candidates, if approved; the risk that the market opportunity for its product candidates may be lower than estimated; and the risk that stable cell line technology is less effective than anticipated or does not yield the expected manufacturing efficiencies. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements.

Other risks and uncertainties faced by Orchard include those identified under the heading "Risk Factors" in Orchards quarterly report on Form 10-Q for the quarter ended March 31, 2020, as filed with the U.S. Securities and Exchange Commission (SEC) on May 7, 2020, as well as subsequent filings and reports filed with the SEC. The forward-looking statements contained in this press release reflect Orchards views as of the date hereof, and Orchard does not assume and specifically disclaims any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law.

Contacts

Investors Renee Leck Director, Investor Relations +1 862-242-0764 Renee.Leck@orchard-tx.com

Media Molly Cameron Manager, Corporate Communications +1 978-339-3378 media@orchard-tx.com

*Zeguer JL, Acors S, Rana B, et al. A BAC-cloning platform for development of stable producer cell lines for commercial scale lentiviral vector manufacture. Hum Gene Ther 2019; 30:11, P056

**PCT/EP2016/078336 and PCT/EP2016/078334

***Source: Malik MA, Masab M. Wiskott-Aldrich Syndrome. [Updated 2019 Jun 22]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2019 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK539838/

Go here to see the original:
Orchard Therapeutics Announces Global License Agreements for Stable Cell Line Technology from GSK - BioSpace

Vertex hires BMS vet Atkinson to shore up manufacturing for bustling cell and gene therapy pipeline – FiercePharma

By Stem Cell Treatment

Vertex has long been known for its cystic fibrosis brand, including fast-growing triple-combo med Trikafta. But Vertex has its eyes on much more than cystic fibrosis with a bustling cell and gene therapy pipeline, and now the company's found the manufacturing chief to help it get there.

Vertex has tapped Bristol Myers Squibb veteran E. Morrey Atkinson, Ph.D., as its senior vice president and head of commercial manufacturing and supply chain to help take the drugmaker's growing portfolio across the regulatory finish line.

Atkinson is the first major C-suite hire under new CEO Reshma Kewalramani, who took the helm earlier this year after switching from the chief medical officer role. His hiring will add an experienced hand in cell and gene therapy manufacturing as Kewalramani steers Vertex's growing and diversifiedpipeline to the commercial stage.

Until June, Atkinsonwas senior vice presidentof global manufacturing operations at Bristol and helped lead the manufacturing integration team for Bristol's $74 billion Celgene merger that closed in November.

In his previous roles at Eli Lilly and Cook Pharmica (now Catalent), Atkinson specialized in biologics manufacturing and led clinical productionfor some of the earliest viral vectors used in cell and gene therapies. Atkinson also spearheaded the building and qualification of commercial production facilities in the U.S. and Ireland, Vertex said.

RELATED:Vertex plans major Boston expansion to support gene, cell therapy ambitions

In June 2019, Vertexunveiled its plan to build a new cell and gene therapies research site in Boston after putting down $420 million to acquire Exonis Therapeutics and expand its existing partnership with CRISPR Therapeutics for multiple Duchenne muscular dystrophy candidates.

Vertex followed that investment up with its $950 million buy of Summa Therapeutics in September, adding the biotech'sstem cell-based diabetes treatments into the mix.

In November,Vertex was reportedly in advanced talks to lease a 256,000-square-foot facility in Boston's Innovation Square to house the drugmaker's planned cell and gene therapy unit.Vertex reportedly scoured the greater Boston region for a new foothold, including sites in Cambridge, Waltham and Watertown, but picked Innovation Square because its one of the most advanced projects in the neighborhood, on track to open in 2021.

So far, Vertexhasn't publicly announced the future home for its advanced therapies unit, though.The drugmaker is also running small-molecule investigational candidates in APOL1-mediated kidneydisease, beta thalassemia, sickle disease and alpha-1 antitrypsin deficiency through clinical testing.

RELATED:Vertex CEO Leiden touts gangbusters Trikafta launch in 'mic drop' earnings call

In the meantime, Vertex currently houses its entire continuous manufacturing center for its cystic fibrosis portfolio at a South Boston facility that employs 100, the drugmaker said.

That site has been running at full speed with sales for Vertex's latest CF launch, Trikafta, blowing past analyst consensus on its way to blockbuster status.

In the first quarter, Trikafta hit $895 million in sales after just five months on the market.Those sales are higher than Vertex's three established CF meds combined and put the drug well on track to hitSVB Leerink analyst GeoffreyPorges' prediction of$4.6 billion in annual sales by 2023 and $6.6 billion in 2025.

Trikafta's gangbusters launch came as a fitting sendoff for CEO Jeffrey Leiden, who moved over into the chairman role in favor of then-CMO Kewalramani.

See the original post here:
Vertex hires BMS vet Atkinson to shore up manufacturing for bustling cell and gene therapy pipeline - FiercePharma

Gene Therapy Market Forecast Booming by Size, Revenue, Trend and Top Growing Companies 2026 – 3rd Watch News

By Stem Cell Treatment

Transparency Market Research (TMR) has published a new report titled,Gene Therapy Market Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 20182026.According to the report, theglobal gene therapy marketwas valued at US$ 17.0 Mn in 2017 and is projected to expand at a CAGR of 40.0% from 2018 to 2026. New product approvals, promising therapeutic outcomes of gene therapy, and high prevalence of non-Hodgkin Lymphoma are anticipated to drive the global market in the next few years. Europe is projected to dominate the global gene therapy market, followed by U.S., by the end of 2026.

Potential unmet needs in the fields of oncology, rare genetic disorders in the U.S. and Europe, new product approvals and commercialization, and high clinical R&D budgets are likely to drive the gene therapy market in these regions during the forecast period. The gene therapy market in Rest of World is projected to expand at a significant CAGR during the forecast period. The high growth rate is attributed to the anticipated approval and commercialization of gene therapy products in developed countries such as Japan, Australia & New Zealand, GCC countries, and China, and high prevalence of non-Hodgkin Lymphoma and head and neck cancers.

View Report :https://www.transparencymarketresearch.com/gene-therapy-market.html

New product approvals & commercialization drives market

2016, 2017, and 2018 were key milestones in the history of the gene therapy market in the U.S. and Europe, as around four gene therapy products have been approved and commercialized. These products are currently in the infancy stage of commercialization, and have exhibited highly positive therapeutic outcomes.

Get PDF Sample Copy of Report: (Including TOC, List of Tables & Figures, Chart) :https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=60429

For instance, in May 2016, GlaxoSmithKline (GSK) gene therapy product, Strimvelis, received marketing approval for the treatment of patients with a very rare disease called ADA-SCID (Severe Combined Immunodeficiency, due to Adenosine Deaminase deficiency). Strimvelis is the first ex-vivo stem cell gene therapy to be approved in Europe for the treatment of ADA-SCID. Furthermore, in August 2017, the USFDA approved Novartis AGs flagship gene therapy product, Kymriah, for the treatment of children and adults up to the age of 25 years affected with B-cell precursor acute lymphoblastic leukemia (ALL). Thus, recent approvals of gene therapy products in the U.S. and Europe for the treatment of various life threatening disorders is projected to fuel the gene therapy market during the forecast period.

Yescarta to be highest revenue generating gene therapy product

The report offers a detailed segmentation of the global gene therapy market based on different gene therapy products approved and commercialized. Based on product, the global gene therapy market has been segmented into Yescarta, Kymriah, Luxturna, Strimvelis, and Gendicine. Yescarta (Axicabtagene Ciloleucel) is a genetically modified autologous Chimeric Antigen Receptor T (CAR T) cell immunotherapy developed by Gilead Sciences, Inc. for the treatment of adult patients with relapsed or refractory large B-cell lymphoma including diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL). It is the first CAR T therapy approved by the US FDA for the treatment of DLBCL. The Yescarta segment is projected to dominate the global gene therapy market by the end of 2026. Anticipated commercialization of Yescarta in Europe and other developed countries and increasing number of treatment centers are key factors that are likely to lead to the dominant share held by Yescarta by the end of 2026.

REQUEST FOR COVID19 IMPACT ANALYSIS https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=1838

Oncology segment to account for high market share

In terms of application, the global gene therapy market has been segmented into ophthalmology, oncology, and adenosine deaminase ?deficient severe combined immunodeficiency (ADA-SCID). The oncology segment is likely to account for a significant share of the market by the end of 2026. Oncology is a highly studied medical field in the clinical pipeline studies of gene therapy candidates. More than 60% of gene therapy clinical research studies are focused on oncology. The large share held by the oncology segment is attributed to the approval and commercialization of Yescarta and Kymriah, in the last one to two years, for the treatment of certain types of non-Hodgkin lymphoma in the U.S. and Europe. Furthermore, increase in demand for Gendicine in China for the treatment of head and neck cancers is projected to drive the segment during the forecast period.

Buy Report Now :https://www.transparencymarketresearch.com/checkout.php?rep_id=1838&ltype=S

Europe offers high incremental opportunity

The gene therapy market in Europe is projected to expand at a significant CAGR of 30.6% during the forecast period. Large number of patient population with refractory large B-cell lymphoma, including diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL), promising therapeutic outcomes, rising demand for gene therapy treatment, and increasing number of gene therapy treatment centers in Europe are key factors that are likely to fuel the gene therapy market in Europe. Moreover, different pricing models are being evaluated by payers and governments to enable access to high priced gene therapy products. This is likely to drive the demand for gene therapy products in Europe during the forecast period.

Read our Case study at :https://www.transparencymarketresearch.com/casestudies/innovative-medical-device-manufacturing-start-up

Large number of clinical pipeline studies and significant investments in gene therapy to gain the first mover advantage

The global gene therapy market is highly consolidated, with very few global players accounting for a major share. Currently, only five companies; Gilead life Sciences Inc. Spark Therapeutic Inc., Novartis AG, Sibiono GeneTech Co. Ltd, and Orchard Therapeutics Limited offer gene therapy products in the market. Most biopharmaceutical companies have invested significantly in clinical R&D for the development of gene therapy products for different chronic and genetic disorders. Large number of gene therapy products are under different stages of clinical pipeline studies, and the number of gene therapy candidates is projected to rise consistently during the forecast period. For instance, according to the Journal of Gene Medicine, there were around 2,597 gene therapy candidates under clinical trials, as of 2017. Of the total clinical studies, around 65% of studies were focused on oncology, 11% of studies were focused on monogenetic field, 7% on infectious diseases and cardiovascular disease, each.

More Trending Reports by Transparency Market Research 1.https://www.prnewswire.com/news-releases/global-radiation-therapy-market-to-reach-us-8-6-bn-by-2026product-approvals-to-drive-growth-transparency-market-research-300998453.html

2.https://www.biospace.com/article/dna-test-kits-market-increase-in-demand-for-ancestry-testing-to-drive-market/

View original post here:
Gene Therapy Market Forecast Booming by Size, Revenue, Trend and Top Growing Companies 2026 - 3rd Watch News

Stem Cell Concentration System Market Is Forecasted To Register A CAGR Growth Of XX% Between And 2018 2028 – Jewish Life News

By Stell Cell Research

Global Stem Cell Concentration System market size will reach xx million US$ by 2025, from xx million US$ in 2018, at a CAGR of xx% during the forecast period. In this study, 2018 has been considered as the base year and 2019-2025 as the forecast period to estimate the market size for Stem Cell Concentration System .

This industry study presents the global Stem Cell Concentration System market size, historical breakdown data (2014-2019) and forecast (2019-2025). The Private Plane production, revenue and market share by manufacturers, key regions and type; The consumption of Stem Cell Concentration System market in volume terms are also provided for major countries (or regions), and for each application and product at the global level.

Request Sample Report @ https://www.futuremarketinsights.co/reports/sample/REP-GB-7707

Global Stem Cell Concentration System market report coverage:

The Stem Cell Concentration System market report covers extensive analysis of the market scope, structure, potential, fluctuations, and financial impacts. The report also enfolds the precise evaluation of market size, share, product & sales volume, revenue, and growth rate. It also includes authentic and trustworthy estimations considering these terms.

The Stem Cell Concentration System market has been reporting substantial growth rates with considerable CAGR for the last couple of decades. According to the report, the market is expected to grow more vigorously during the forecast period and it can also influence the global economic structure with a higher revenue share. The market also holds the potential to impact its peers and parent market as the growth rate of the market is being accelerated by increasing disposable incomes, growing product demand, changing consumption technologies, innovative products, and raw material affluence.

The following manufacturers are covered in this Stem Cell Concentration System market report:

Key Players

Some of the global key participants operating in stem cell concentration system market are: EmCyte Corporation, Zimmer Biomet, Harvest Technologies, Argos Technologies, Inc., Perkin Elmer, Inc., Arthrex, Inc., Avita Medical, Teleflex, Inc., Terumo Corporation and others

The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to market segments such as geographies, application, and industry.

The report covers exhaust analysis on:

Regional analysis includes:

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

Report Highlights:

NOTE All statements of fact, opinion, or analysis expressed in reports are those of the respective analysts. They do not necessarily reflect formal positions or views of Future Market Insights.

Request Methodology On This Report @ https://www.futuremarketinsights.co/askus/REP-GB-7707

The study objectives are Stem Cell Concentration System Market Report:

We offer tailor-made solutions to fit your requirements, request[emailprotected] https://www.futuremarketinsights.co/customization-available/REP-GB-7707

This report includes the estimation of market size for value (million USD) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Stem Cell Concentration System market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Excerpt from:
Stem Cell Concentration System Market Is Forecasted To Register A CAGR Growth Of XX% Between And 2018 2028 - Jewish Life News

→←